ArticlePituitary2026
Individualized gamma knife radiosurgery prescription dosing for pituitary adenomas: development and internal validation of a feedforward neural network model.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- AI for prognosis and treatment stratification in glioblastoma neurosurgery: a systematic review.Journal of neuro-oncology · 2026Pooled it
- Predicting time to local failure after gamma knife radiosurgery for melanoma brain metastases using survival machine learning.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Therapeutic Hybrid Intelligence with Neural and Knowledge-based Expert Reasoning for SRS (THINKERS): an AI Model for Functional Outcome Prediction After Gamma Knife Thalamotomy for Essential Tremor.Cerebellum (London, England) · 2026Article
- Pituitary Society Delphi consensus on the role of radiotherapy for pituitary adenomas.Pituitary · 2026Review
- Internal validation of THINKERS-PA for outcome prediction after pituitary adenoma radiosurgery.Pituitary · 2026Article
- Machine Learning Prediction of Local Failure in GI Brain Metastases on the Day of Gamma Knife Radiosurgery.Journal of gastrointestinal cancer · 2026Article
- Local control and dose selection for lung cancer brain metastases treated with radiosurgery: an artificial intelligence model.Clinical & experimental metastasis · 2026Article
- Clinical GBM hybrid artificial intelligence for prescription dose recommendation and outcome prediction after gamma knife radiosurgery treatment: a proof-of-concept.Frontiers in oncology · 2026Article
- Therapeutic hybrid intelligence with neural and knowledge-based expert reasoning for SRS: an AI model for breast cancer brain metastases.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGamma Knife radiosurgery (GKRS) is an established treatment for pituitary adenomas yet prescription dose selection is often guided by clinician experience. Data-driven models may help standardize dose selection using routinely available clinical and imaging features.
objectiveTo develop and internally validate a feedforward neural network (FNN) to predict GKRS prescription dose for pituitary adenomas.
methodsWe retrospectively analyzed 102 pituitary adenomas treated with GKRS at a single center. Model inputs included age at treatment, sex, race, pre-treatment Karnofsky Performance Status (KPS), functional or secretory status, histology, prior tumor resection, prior stereotactic radiosurgery, tumor volume, and cavernous sinus invasion. The target outcome was GKRS prescription dose (Gy). Data were randomly split into training and test sets (80:20). Features were standardized and one-hot encoded. A multivariable FNN with two hidden layers was trained, and test performance was evaluated using mean absolute error (MAE), root mean squared error (RMSE), and coefficient of determination (R²). Permutation importance was used to assess predictor contribution.
resultsOn the test set, the FNN achieved an MAE of 1.61 Gy, RMSE of 2.31 Gy, and R² of 0.51. Age at treatment showed the greatest contribution (ΔMAE +0.89 Gy with permutation), followed by functional or secretory status, tumor volume, cavernous sinus invasion, and pre-treatment KPS. Demographic variables and biopsy-related factors had minimal impact.
conclusionsThis proof-of-concept FNN generated individualized GKRS prescription dose estimates for pituitary adenomaswith acceptable prediction error, supporting the feasibility of data-driven dose recommendation tools and motivating external validation in larger, multi-institutional cohorts.
Indexed as
Identifiers
41663852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.